Pharmaceutical Research

, Volume 27, Issue 11, pp 2374–2383

Crystallization of Trehalose in Frozen Solutions and its Phase Behavior during Drying

  • Prakash Sundaramurthi
  • Thomas W. Patapoff
  • Raj Suryanarayanan
Research Paper



(i) To study the crystallization of trehalose in frozen solutions and (ii) to understand the phase transitions during the entire freeze-drying cycle.


Aqueous trehalose solution was cooled to −40°C in a custom-designed sample holder. The frozen solution was warmed to −18°C and annealed, and then dried in the sample chamber of the diffractometer. XRD patterns were continuously collected during cooling, annealing and drying.


After cooling, hexagonal ice was the only crystalline phase observed. However, upon annealing, crystallization of trehalose dihydrate was evident. Seeding the frozen solution accelerated the solute crystallization. Thus, phase separation of the lyoprotectant was observed in frozen solutions. During drying, dehydration of trehalose dihydrate yielded a substantially amorphous anhydrous trehalose.


Crystallization of trehalose, as trehalose dihydrate, was observed in frozen solutions. The dehydration of the crystalline trehalose dihydrate to substantially amorphous anhydrate occurred during drying. Therefore, analyzing the final lyophile will not reveal crystallization of the lyoprotectant during freeze-drying. The lyoprotectant crystallization can only become evident by continuous monitoring of the system during the entire freeze-drying cycle. In light of the phase separation of trehalose in frozen solutions, its ability to serve as a lyoprotectant warrants further investigation.


in situ freeze-drying XRD lyoprotectant crystallization phase transformation trehalose 


  1. 1.
    Pikal MJ. Freeze drying. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology, vol. 1. New York: Informa healthcare; 2007. p. 1807–33.Google Scholar
  2. 2.
    Anhorn MG, Mahler H-C, Langer K. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm. 2008;363:162–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Imamura K, Asano Y, Maruyama Y, Yokoyama T, Nomura M, Ogawa S, et al. Characteristics of hydrogen bond formation between sugar and polymer in freeze-dried mixtures under different rehumidification conditions and its impact on the glass transition temperature. J Pharm Sci. 2008;97:1301–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Izutsu K, Yoshioka S, Takeda Y. The effects of additives on the stability of freeze-dried beta -galactosidase stored at elevated temperature. Int J Pharm. 1991;71:137–46.CrossRefGoogle Scholar
  5. 5.
    Izutsu K, Yoshioka S, Terao T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm Res. 1993;10:1232–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Randolph TW. Phase separation of excipients during lyophilization: effects on protein stability. J Pharm Sci. 1997;86:1198–203.CrossRefPubMedGoogle Scholar
  7. 7.
    Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14:969–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Chatterjee K, Shalaev EY, Suryanarayanan R. Raffinose crystallization during freeze-drying and its impact on recovery of protein activity. Pharm Res. 2005;22:303–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Coutinho C, Bernardes E, Felix D, Panek AD. Trehalose as cryoprotectant for preservation of yeast strains. J Biotechnol. 1988;7:23–32.CrossRefGoogle Scholar
  10. 10.
    Crowe JH, Carpenter JF, Crowe LM. The role of vitrification in anhydrobiosis. Annu Rev Physiol. 1998;60:73–103.CrossRefPubMedGoogle Scholar
  11. 11.
    Crowe LM, Reid DS, Crowe JH. Is trehalose special for preserving dry biomaterials? Biophys J. 1996;71:2087–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Lu X, Pikal MJ. Freeze-drying of mannitol-trehalose-sodium chloride-based formulations: The impact of annealing on dry layer resistance to mass transfer and cake structure. Pharm Dev Technol. 2004;9:85–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Akers MJ. Excipient—drug interactions in parenteral formulations. J Pharm Sci. 2002;91:2283–300.CrossRefPubMedGoogle Scholar
  14. 14.
    Surana R, Pyne A, Suryanarayanan R. Effect of aging on the physical properties of amorphous trehalose. Pharm Res. 2004;21:867–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res. 2004;21:1167–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Miller DP, De Pablo JJ. Calorimetric solution properties of simple saccharides and their significance for the stabilization of biological structure and function. J Phys Chem B. 2000;104:8876–83.CrossRefGoogle Scholar
  17. 17.
    Bubnik Z, Kadlec P. Sucrose solubility. In: Mathlouthi M, Reiser P, editors. Sucrose properties and applications. Glasgow: Blackie Academic & Processional; 1995. p. 101–25.Google Scholar
  18. 18.
    Miller DP, De Pablo JJ, Corti H. Thermophysical properties of trehalose and its concentrated aqueous solutions. Pharm Res. 1997;14:578–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Green JL, Angell CA. Phase relations and vitrification in saccharide-water solutions and the trehalose anomaly. J Phys Chem. 1989;93:2880–2.CrossRefGoogle Scholar
  20. 20.
    Nicolajsen H, Hvidt A. Phase behavior of the system trehalose-NaCl-water. Cryobiology. 1994;31:199–205.CrossRefGoogle Scholar
  21. 21.
    Sundaramurthi P, Suryanarayanan R. Trehalose crystallization during freeze-drying: Implications on lyoprotection. J Phys Chem Lett. 2010;1:510–4.CrossRefGoogle Scholar
  22. 22.
    Akers MJ, Vasudevan V, Stickelmeyer M. Formulation development of protein dosage forms. Pharm Biotechnol. 2002;14:47–127.PubMedGoogle Scholar
  23. 23.
    Han J, Suryanarayanan R. Influence of environmental conditions on the kinetics and mechanism of dehydration of carbamazepine dihydrate. Pharm Dev Technol. 1998;3:587–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Han J, Suryanarayanan R. A method for the rapid evaluation of the physical stability of pharmaceutical hydrates. Thermochim Acta. 1999;329:163–70.CrossRefGoogle Scholar
  25. 25.
    Allison SD, Chang B, Randolph TW, Carpenter JF. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch Biochem Biophys. 1999;365:289–98.CrossRefPubMedGoogle Scholar
  26. 26.
    Sundaramurthi P, Shalaev E, Suryanarayanan R. “pH swing” in frozen solutions-consequence of sequential crystallization of buffer components. J Phys Chem Lett. 2010;1:265–8.CrossRefGoogle Scholar
  27. 27.
    Sundaramurthi P, Shalaev E, Suryanarayanan R. Calorimetric and diffractometric evidence for the sequential crystallization of buffer components and consequent pH swing in frozen solutions. J Phys Chem B. 2010;114:4915–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Moore TW. Dissolution testing: a fast, efficient procedure for degassing dissolution medium. Dissolution Technol. 1996;3:3–5.Google Scholar
  29. 29.
    Powder Diffraction File. Hexagonal ice, card # 00-042-1142; D-trehalose dihydrate, card # 00-029-1955; trehalose anhydrate, card # 00-003-0312. International Centre for Diffraction Data, Newtown Square, PA (2004).Google Scholar
  30. 30.
    Varshney DB, Kumar S, Shalaev EY, Sundaramurthi P, Kang S-W, Gatlin LA, et al. Glycine crystallization in frozen and freeze-dried systems: effect of pH pH and buffer concentration. Pharm Res. 2007;24:593–604.CrossRefPubMedGoogle Scholar
  31. 31.
    Pyne A, Chatterjee K, Suryanarayanan R. Crystalline to amorphous transition of disodium hydrogen phosphate during primary drying. Pharm Res. 2003;20:802–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Sundaramurthi P, Suryanarayanan R. Influence of crystallizing and non-crystallizing cosolutes on trehalose crystallization during freeze-drying. Pharm Res. 2010; doi:10.1007/s11095-010-0221-8.

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Prakash Sundaramurthi
    • 1
    • 2
  • Thomas W. Patapoff
    • 3
  • Raj Suryanarayanan
    • 1
  1. 1.Department of Pharmaceutics, College of PharmacyUniversity of MinnesotaMinneapolisUSA
  2. 2.Scientific Affairs, Teva Parenteral Medicines Inc.IrvineUSA
  3. 3.Early Stage Pharmaceutical Research and Development Genentech, Inc.South San FranciscoUSA

Personalised recommendations